Piper Jaffray Upgrades Acadia Pharmaceuticals (ACAD) to Overweight
Tweet Send to a Friend
Piper Jaffray analyst Danielle Brill upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral to Overweight with a price target of $25.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
